Literature DB >> 27614168

Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats.

Lorena A Vargas1, Oscar A Pinilla1, Romina G Díaz1, Diana E Sepúlveda2, Erik R Swenson3, Néstor G Pérez1, Bernardo V Álvarez4.   

Abstract

BACKGROUND: Two potent carbonic anhydrase (CA) inhibitors with widely differing membrane permeability, poorly diffusible benzolamide (BZ), and highly diffusible ethoxzolamide (ETZ) were assessed to determine whether they can reduce cardiac dysfunction in rats subjected to coronary artery ligation (CAL)-induced myocardial infarction. METHODS AND
RESULTS: Rats with evidence of heart failure (HF) at 32 weeks following a permanent left anterior coronary artery occlusion were treated with placebo, BZ, or ETZ (4 mg kgday-1) for 4 weeks at which time left ventricular function and structure were evaluated. Lung weight/body weight (LW/BW) ratio increased in CAL rats by 17±1% vs. control, suggesting pulmonary edema. There was a trend for BZ and ETZ to ameliorate the increase in LW/BW by almost 50% (9±5% and 9±8%, respectively, versus CAL) (P=.16, NS). Echocardiographic assessment showed decreased left ventricular midwall shortening in HF rats, 21±1% vs. control 32±1%, which was improved by BZ to 29±1% and ETZ to 27±1%, and reduced endocardial shortening in HF rats 38±3% vs. control 62±1%, partially restored by BZ and ETZ to ~50%. Expression of the hypoxia-inducible membrane-associated CAIX isoform increased by ~60% in HF rat hearts, and this effect was blocked by ETZ.
CONCLUSIONS: We conclude that CAL-induced myocardial interstitial fibrosis and associated decline in left ventricular function were diminished with BZ or ETZ treatment. The reductions in cardiac remodeling in HF with both ETZ and BZ CA inhibitors suggest that inhibition of a membrane-bound CA appears to be the critical site for this protection.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carbonic anhydrase inhibitors; Heart failure; Intracellular pH; Myocardial infarction

Mesh:

Substances:

Year:  2016        PMID: 27614168     DOI: 10.1016/j.carpath.2016.08.003

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  5 in total

1.  Functional and Molecular Characterisation of Heart Failure Progression in Mice and the Role of Myosin Regulatory Light Chains in the Recovery of Cardiac Muscle Function.

Authors:  Kasturi Markandran; Haiyang Yu; Weihua Song; Do Thuy Uyen Ha Lam; Mufeeda Changaramvally Madathummal; Michael A Ferenczi
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  Myocardial and mitochondrial effects of the anhydrase carbonic inhibitor ethoxzolamide in ischemia-reperfusion.

Authors:  Alejandro Ciocci Pardo; Luisa F González Arbeláez; Juliana C Fantinelli; Bernardo V Álvarez; Susana M Mosca; Erik R Swenson
Journal:  Physiol Rep       Date:  2021-11

Review 3.  Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer's Disease and Stroke.

Authors:  Nicole Lemon; Elisa Canepa; Marc A Ilies; Silvia Fossati
Journal:  Front Aging Neurosci       Date:  2021-11-16       Impact factor: 5.750

4.  Network Pharmacology-Based Analysis of the Pharmacological Mechanisms of Aloperine on Cardiovascular Disease.

Authors:  Bingwu Huang; Juncheng Xiong; Xuyong Zhao; Yihan Zheng; Ning Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-14       Impact factor: 2.629

5.  Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension.

Authors:  Fotios Spyropoulos; Zoe Michael; Benjamin Finander; Sally Vitali; Kosmas Kosmas; Panagiotis Zymaris; Brian T Kalish; Stella Kourembanas; Helen Christou
Journal:  Front Cardiovasc Med       Date:  2021-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.